Quote:The Steele Dossier: A Retrospective
https://www.lawfareblog.com/steele-dossier-retrospective
By Sarah Grant, Chuck Rosenberg
Friday, December 14, 2018, 8:00 AM
The dossier is actually a series of reports—16 in all—that total 35 pages. Written in 2016, the dossier is a collection of raw intelligence. Steele neither evaluated nor synthesized the intelligence. He neither made nor rendered bottom-line judgments. The dossier is, quite simply and by design, raw reporting, not a finished intelligence product.
In that sense, the dossier is similar to an FBI 302 form or a DEA 6 form. Both of those forms are used by special agents of the FBI and DEA, respectively, to record what they are told by witnesses during investigations. The substance of these memoranda can be true or false, but the recording of information is (or should be) accurate. In that sense, notes taken by a special agent have much in common with the notes that a journalist might take while covering a story—the substance of those notes could be true or false, depending on what the source tells the journalist, but the transcription should be accurate.
With that in mind, we thought it would be worthwhile to look back at the dossier and to assess, to the extent possible, how the substance of Steele’s reporting holds up over time. In this effort, we considered only information in the public domain from trustworthy and official government sources, including documents released by Special Counsel Robert Mueller’s office in connection with the criminal cases brought against Paul Manafort, the 12 Russian intelligence officers, the Internet Research Agency trolling operation and associated entities, Michael Cohen, Michael Flynn and George Papadopoulos. We also considered the draft statement of offense released by author Jerome Corsi, a memorandum released by House Permanent Select Committee on Intelligence Ranking Member Adam Schiff related to the Carter Page FISA applications and admissions directly from certain speakers.
These materials buttress some of Steele’s reporting, both specifically and thematically. The dossier holds up well over time, and none of it, to our knowledge, has been disproven.
But much of the reporting simply remains uncorroborated, at least by the yardstick we are using. Most significantly, the dossier reports a “well-developed conspiracy of co-operation between [Trump and his associates] and the Russian leadership,” including an “intelligence exchange [that] had been running between them for at least 8 years.”
There has been significant investigative reporting about long-standing connections between Trump, his associates and Kremlin-affiliated individuals, and Trump himself acknowledged that the purpose of a June 2016 meeting between his son, Donald Trump Jr. and a Kremlin-connected lawyer was to obtain “dirt” on Hillary Clinton.
But there is, at present, no evidence in the official record that confirms other direct ties or their relevance to the 2016 presidential campaign. With that caveat, here are excerpts from the dossier that correspond with details contained in official documents.
As we noted, our interest is in assessing the Steele dossier as a raw intelligence document, not a finished piece of analysis. The Mueller investigation has clearly produced public records that confirm pieces of the dossier. And even where the details are not exact, the general thrust of Steele’s reporting seems credible in light of what we now know about extensive contacts between numerous individuals associated with the Trump campaign and Russian government officials.
However, there is also a good deal in the dossier that has not been corroborated in the official record and perhaps never will be—whether because it’s untrue, unimportant or too sensitive.
As a raw intelligence document, the Steele dossier, we believe, holds up well so far. But surely there is more to come from Mueller’s team. We will return to it as the public record develops.
NOT BS and none of it was material to Mueller's
Top 10 Most Recent News Articles
Leqembi Pen Revolutionizes Alzheimer's Care in Japan
Innovative Alzheimer's Treatment Hits Japanese Market Just when you think the medical world needs a jolt of innovation, BioArctic rolls out something that could change how Alzheimer's is managed. With their subcutaneous Leqembi Pen, they've just added another feather in their cap, launching in Japan after a successful U.S. introduction. Not just your run-of-the-mill...
Continue Reading
Randi Baptiste Sets a New Standard in Youth Sports
Youth Sports: Revolutionized by Randi Baptiste In an era where youth sports face a minefield of health risks and performance pressures, Randi Baptiste stands out. This isn't just about running around the park—this is about fundamentally transforming how we think about athletic development for young folks. Recognizing Baptiste for his contributions, The Inner Circle...
Continue Reading
Simform's AI Innovations Earns Microsoft Award Nod
Riding the AI Wave with Simform In the chaotic world of AI and tech partnerships, earning recognition from a powerhouse like Microsoft ain't your run-of-the-mill achievement. Simform being recognized as a finalist for the 2026 Microsoft Innovate with Azure AI Apps and Agents Partner of the Year Award is a big deal, not just for them, but as a beacon of inspiration for...
Continue Reading
GAC's Green Push Unveils 3rd Showroom in Casablanca
Pushing Through North Africa's Automotive Shift Well, looks like GAC is showing they're not just dabbling in North Africa—they're planting some sturdy roots in that rocky soil. Opening their third showroom in Casablanca, GAC isn't just settling for sidelines. They're step-in-the-ring serious about carving their name on North African roads. This isn't some skin-deep...
Continue Reading
Adam Foundation's Ramadan Effort to Cut Plastic Waste
Environmental Consciousness: A Call from Antalya Here we go again, folks. Something refreshing is brewing over in Antalya at COP31, where the UK-based Adam Foundation has made a move that resonates beyond the usual hubbub. No smoke and mirrors, just straightforward action aimed at cutting down the wave of plastic waste during Ramadan. This isn't some pie-in-the-sky green...
Continue Reading
FF EAI Robotics Aims for Top Spot in K-12 Tech
FFR's Shot at Robotics Education Dominance You ever feel like a company is throwing everything but the kitchen sink at an opportunity? That's FF EAI Robotics for you—charging ahead with a hefty laundry list of tech ambitions. They've clocked in about $2.3 million in revenue from their newly acquired robotics wing for the first nine months of 2026, showing a 26% gross...
Continue Reading
Rethinking Risk: AI, Cyber, and Ops Convergence
Risk Management's New Frontier Hold onto your hats, folks, because the landscape of risk management is shifting under our feet—and not a minute too soon. With AI adoption skyrocketing, cybersecurity threats piling up like never-ending junk mail, and operational hurdles lurking around every corner, Wipfli's throwing down the gauntlet for business leaders to wise up....
Continue Reading
Implantica's Q3 2026: A Potential Leap Forward?
Implantica Prepares to Unveil Q3 Results We're heading into the home stretch for 2026, and Implantica's about to unveil its third-quarter results. With its presentation scheduled for November 19 at 15:00 CET, this medtech outfit has caught some eyes, especially with their flagship offering, RefluxStop®. Paying attention here might be worthwhile, as this plays into a...
Continue Reading
Squeez and Qentelli Join Forces to Revolutionize Loyalty
A New Era of Loyalty Commerce The winds are changing in the loyalty game, and it's about time someone shook things up. Squeez has teamed up with Qentelli, thanks to a $1 million investment, to kick-start this next wave of commerce. And boy, it's not just about money—it's like combining brains with brawn. Squeez isn't just offering loyalty programs anymore; they're...
Continue Reading
Vipshop Sets 2026 AGM: Shareholders Meet on Dec 8
Blockbuster or Bust: Vipshop's Upcoming AGM Here's the scoop: Vipshop Holdings Limited, with its mammoth operations in China's off-price retail sector, is gearing up for its annual general meeting (AGM) on December 8, 2026. This is where management and stakeholders will hash out everything from strategic pivots to financial health. Forget shareholder votes this...
Continue ReadingTop 5 Most Recently Viewed Articles
Actinium Pharmaceuticals Faces Class Action Lawsuit for Losses
Actinium Pharmaceuticals: A Closer Look at the Lawsuit Recently, a significant class action lawsuit was filed against Actinium Pharmaceuticals, Inc. (NYSE: ATNM). This legal action is vital for investors who have experienced financial losses associated with their investments in Actinium's stock. The lawsuit, initiated by Pomerantz LLP, accuses the company and some of its...
Continue Reading
Uranium Energy Corp Delivers Promising Drill Results at Roughrider
Uranium Energy Corp Unveils Outstanding Drilling Results Uranium Energy Corp (NYSE American: UEC) is thrilled to share the latest findings from its active drilling campaign at the Roughrider Project, which have revealed striking high-grade uranium mineralization. A drill hole positioned 850 meters northeast of the central Roughrider deposit has showcased remarkable...
Continue Reading
TME Pharma Presents Promising Glioblastoma Trial Outcomes
TME Pharma's Progress in Glioblastoma Treatment TME Pharma N.V. is a clinical-stage biotechnology company dedicated to developing innovative therapies for cancer. Recently, they announced an important oral presentation at a renowned medical congress, showcasing the encouraging results from the NOX-A12 GLORIA Phase 1/2 trial. This study aims to address glioblastoma, a...
Continue Reading
Life Time Champions Expanding Pickleball Facilities Across U.S.
Life Time Champions Expanding Pickleball Facilities Across U.S. Life Time (NYSE: LTH) proudly marks World Pickleball Day as the sport continues to gain unprecedented popularity across America. With over 750 permanent pickleball courts established within its athletic country clubs, the organization demonstrates its commitment to being at the forefront of this dynamic...
Continue Reading
Edgewise Therapeutics Shares Breakthrough EDG-7500 Results
Edgewise Therapeutics Announces Significant Progress in Hypertrophic Cardiomyopathy Treatment Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a pioneering biopharmaceutical company focused on muscle diseases, has recently disclosed positive outcomes from their Phase 2 CIRRUS-HCM trial studying EDG-7500. This treatment targets hypertrophic cardiomyopathy (HCM), a serious...
Continue Reading